 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | igenetech Inc. |
| Street 1: | Unit2314, A-dong |
| Street 2: | 58-1 Giheung-ro |
| City: | Yongin-si |
| Province: | |
| Post Code: | 16976 |
| Country: | Republic of Korea |
| Phone: | +82-(0)70-4077-1557 |
| Organization Email: | igenetech@igenetech.co.kr |
| Web Site: | http://www.igenetech.co.kr/eng/ |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 652-87-02299 |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| iGENETECH Inc.is a forward-thinking start-up company driven by innovation and excellence.Our team consists of highly skilled professionals with extensive experience in point-of-care diagnostic platforms, reagents, mass production, and regulatory approval in the in-vitro diagnostics field. Our mission is to provide a best-in-class MDx POC platform for users, offering especially affordable, user-friendly and accurate diagnosis. Tuberculosis is one of the most serious infectious disease to be eliminate in the world, especially in LMIC and restricted resource environment. Our molecular POC platform had been developed to be able to use that kind of environment and approved by Korean Ministry of Food and Drug Safety recently. We have a plan to develop TB-MDR molecular POC reagents can be used on out molecular POC platform. It could be used at primary sector by low level skilled person at restricted resource environment. It also has affordable price. We have completed the development of nucleic acid purification reagents with high yield and purity for tuberculosis sample(especially sputum) and specific primer/probe mixture now, and are developing the primer/probe mixture for the detection of Drug resistance related mutations. |
|
| Do you know about the UNHLM declaration: | No |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 11 - 25 |
| Number of full-time staff who are directly involved with TB: | 1 - 5 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | World TB Day |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| igenetech Inc. is a start-up company that has been establisied in 2022. We have developed the platform device and got approval of device recently. Therefore we are not contributing to our country's national TB control plan until now. | |
Geographical Reach | |
| Which country is your headquarters located in: | Republic of Korea |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Republic of Korea |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: We will develop and commercialize the MDR-TB real time PCR All-in-One Cartridge kit by collaboration with Indian molecular diagnostics company. It will contribute to screen and diagnosis of TB in India and reduce the number of new infection. New Diagnostics: We will develop and commercialize the MDR-TB real time PCR All-in-One Cartridge kit by collaboration with Indian molecular diagnostics company. It will contribute to screen and diagnosis of TB in India and reduce the number of new infection. Our Molecular POC platform could be used in primary sector by less skillful person with low error rate. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | September 20, 2024 |
| Last updated: | March 28, 2025 |